Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines new offering …
Tag:
Lilly's
-
-
Lifestyle & Healthslider
Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
by Karine Ayoubby Karine AyoubIn ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and …
-
Lifestyle & Healthslider
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
by Karine Ayoubby Karine AyoubRevenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from …
-
Lifestyle & Healthslider
Lilly’s baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
by Karine Ayoubby Karine AyoubLate-breaking results presented at AAD show 80% or more scalp hair coverage at Week …
-
Lifestyle & Healthslider
Lilly’s tirzepatide superior to semaglutide in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
by Karine Ayoubby Karine AyoubParticipants using tirzepatide lost 50.3 lbs. (22.8 kg) and participants on semaglutide lost 33.1 …